Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat 3 Stocks Under $5 With Strong Analyst Upside PotentialBy Chris Markoch. Publication Date: 2/24/2026. 
Key Points - Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
- Special Report: [Sponsorship-Ad-6-Format3]
While many investors are rotating out of speculative penny stocks, others still embrace their risk-reward dynamic. Stocks trading under $5 carry significant risk: many are unprofitable, and some generate little or no revenue. These are almost always small-cap companies, a group that has taken heavy losses in recent years. Even though the Russell 2000 shows some recovery, gains haven't been widespread across the broader small-cap sector. Fraud is being exposed everywhere right now. Billions gone.
But they're missing the big one...
A legal scam that affects 95% of ALL Americans.
Oxford Club's own Marc Lichtenfeld hit the streets of South Florida to expose it in broad daylight.
Watch along as he captures real people's reactions LIVE on camera. Click Here to Watch What Happens That could change in 2026 if the economic outlook improves; money may flow back into speculative names. As always, quality matters. One way to filter for quality is to seek names with positive analyst sentiment. That applies to the three stocks below. Each lets an investor start a meaningful position with a modest outlay while retaining the potential for significant upside over the next five years. Profitability Milestone Meets Long-Term Emerging Market Growth Emerging-market stocks are expected to be among the winners in 2026. That hasn't been true so far for Grab Holdings Inc. (NASDAQ: GRAB), which is down about 15% this year. Grab, based in Singapore, operates a super app that combines technology, e-commerce and fintech services. One reason behind the stock's recent pullback is its proposed merger with Indonesian ride-share competitor GoTo. The deal is not final and could face legislative changes in Indonesia that would constrain the company's earnings potential there. The company also missed the top line slightly in its Q4 2025 earnings report. Some context is necessary: revenue rose 19% year over year, and the period marked the first full year of profitability in the company's history. Analysts forecast roughly 120% earnings growth over the next 12 months. That helps explain why sentiment remains bullish. GRAB has a consensus price target of $6.47, implying about 54% upside from its current level. High-Risk Biotech With Platform Potential Penny-stock investors often look to the biotechnology sector, where risk and reward can be pronounced. One name to watch is Vaxart Inc. (OTCMKTS: VXRT). It is the only company on this list that meets the classic definition of a penny stock; at the time of writing it traded just above $0.60 per share. VXRT doesn't have heavy analyst coverage, but the one analyst who rated it in the last 12 months rates it a Buy with a $2 price target. It's common for analysts to avoid early-stage biotech companies. Vaxart is clinical-stage, meaning all of its candidates remain in clinical trials. The potential upside is clear: the company is developing oral vaccines primarily for influenza, norovirus and COVID-19. Beyond convenience—and avoidance of needle-related fear—the company says its platform can elicit a broader immune response that may provide wider protection. VXRT has roughly 18% institutional ownership. In terms of dollar volume, inflows outnumber outflows nearly 10-to-1, which is notable given the low analyst coverage. Resale Tailwinds Could Turn Today's Losses Into Tomorrow's Gains ThredUp Inc. (NASDAQ: TDUP) is down about 33% in 2026, but a wider view is instructive: over the last 12 months TDUP is up more than 66%. That suggests this is a normal pullback at a time when many investors are avoiding companies that aren't yet profitable. In ThredUp's case, the caveat is "yet." The company operates an online consignment and thrift marketplace that is gaining traction with Gen Z. In its most recent quarter, revenue rose 12.5% year over year. ThredUp cites a GlobalData 2025 market survey that forecast the U.S. secondhand market's gross merchandise value would grow at a compound annual growth rate (CAGR) of 9% through 2029. Institutions own roughly 89% of the stock. In dollar terms, buying has outpaced selling about two-to-one, and on a share-count basis buying exceeds selling roughly three-to-one. That said, short interest sits around 17%, which can add near-term volatility. The consensus price target from six analysts is $12.50, which would represent an increase of more than 190% from its current price.
| 
